Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors
NCT00875004 · Institut du Cancer de Montpellier - Val d'Aurelle · NA · terminated · last registry update 2024-06-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “After two years of trial initiation, only 27 out of 300 patients were included. During this period, the international recommendations for the use of COOL were modified.” | – | Registry record, Institut du Cancer de Montpellier - Val d'Aurelle |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EPOR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-06-17Phase 3 first posted: Incepta Pharmaceuticals Ltd, Erythropoietin alfa (NCT07025681)
- 2025-05-22Results posted on the registry: Akebia Therapeutics, Vadadustat + Darbepoetin alfa (NCT04313153)
- 2025-04-18Results posted on the registry: United States Army Research Institute of Environmental Medicine, Epoetin Alfa (NCT05078138)
- 2025-04-06Results posted on the registry: Mayo Clinic, Iron Dextran + Erythropoietin (EPO) (NCT05167734)
- 2025-03-20Results posted on the registry: Bio Sidus SA, Erythropoietin alfa (NCT04036253)
- 2025-01-22Results posted on the registry: National Cancer Institute (NCI), Ibrutinib + Steroid pulse (prednisone) (NCT04294641)
- 2025-01-15Results posted on the registry: Akebia Therapeutics, Vadadustat + Mircera® (NCT04707768)
- 2024-12-13Results posted on the registry: Syros Pharmaceuticals, Tamibarotene + Azacitidine (NCT02807558)
- 2024-12-09Also stopped (terminated): Hospital Son Espases, Paricalcitol + Epoetin beta (NCT02876211)
- 2024-12-06Phase 3 first posted: Shenzhen Salubris Pharmaceuticals Co., Ltd., SAL-0951 tablets + rHuEPO injection (NCT06720025)
- 2024-10-30Results posted on the registry: NICHD Neonatal Research Network, Darbepoetin + Placebo (NCT03169881)
- 2024-10-04Also stopped (terminated): Belfast Health and Social Care Trust, ARA290 (NCT06626971)
- 2024-08-23Results posted on the registry: Universitaire Ziekenhuizen KU Leuven, Antithrombin-III + Infliximab (NCT02251041)
- 2024-08-01Results posted on the registry: Kyntra Bio, Roxadustat + Placebo (NCT03263091)
- 2024-08-01Also stopped (terminated): Kyntra Bio, Roxadustat + Placebo (NCT03263091)
- 2024-07-25Phase 3 first posted: USRC Kidney Research, Vadadustat + Erythropoiesis Stimulating Agent (NCT06520826)
- 2024-06-26Results posted on the registry: Celgene, Luspatercept + Epoetin alfa (NCT03682536)
- 2024-06-20Phase 3 first posted: Genexine, Inc., Efepoetin Alfa + Darbepoetin Alfa (NCT06466785)
- 2024-04-22Results posted on the registry: AstraZeneca, Roxadustat + rHuEPO (NCT04655027)
- 2024-04-08Phase 3 first posted: Megalabs, Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration. + Active comparator: European Union licenced epoetin alfa (NCT06352138)
- 2024-04-02Also stopped (terminated): Ontario Clinical Oncology Group (OCOG), Epoetin Alfa (NCT00310232)
- 2024-03-27Also stopped (terminated): GlaxoSmithKline, Daprodustat + Darbepoetin alfa (NCT03446612)
- 2023-12-29Also stopped (terminated): Children's Hospital of Fudan University, Epo + Normal saline (NCT02550054)
- 2023-11-18Phase 3 first posted: Ain Shams University, erythropoietin + Triamcinolone acetonide (NCT06135259)
- 2023-08-24Results posted on the registry: Celgene, Luspatercept (NCT03194542)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision